Dupixent included in Egypt' s list approved drug that meet urgent clinical need.
Cairo Egypt – The Egyptian Drug Authority - EDA in Egypt has approved Dupixent® (dupilumab) in adults & adolescents 12 years and older for 2 chronic diseases : As a treatment of moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and as an add-on maintenance treatment for severe asthma with type 2 inflammation
"Today's approval marks a significant profound impact on the lives of people with moderate-to-severe atopic dermatitis & severe asthma for adults and adolescents," said Ahmed Hegazy General Manager Sanofi Genzyme in Egypt
He added, “The absence treatment for moderate-to-severe atopic dermatitis has left many patients and their caregivers for them coping with the physical and emotional burden of the disease,”
"Furthermore, people whose severe asthma is inadequately controlled on current therapy continue to have trouble breathing and suffer potentially life-threatening exacerbations. These daily burdens can significantly diminish quality of life, causing missed days of school, work and social activities,
© Press Release 2021